THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

NASDAQ:THTX • CA88338H7040

3.39 USD
0 (0%)
At close: Sep 25, 2025
3.4 USD
+0.01 (+0.29%)
After Hours: 9/25/2025, 8:03:14 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, THTX scores 3 out of 10 in our fundamental rating. THTX was compared to 521 industry peers in the Biotechnology industry. There are concerns on the financial health of THTX while its profitability can be described as average. THTX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • THTX had negative earnings in the past year.
  • In the past year THTX had a positive cash flow from operations.
  • In the past 5 years THTX always reported negative net income.
  • In the past 5 years THTX reported 4 times negative operating cash flow.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • THTX has a better Return On Assets (-17.86%) than 79.10% of its industry peers.
  • With an excellent Return On Invested Capital value of 55.37%, THTX belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROIC 55.37%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

  • Looking at the Operating Margin, with a value of 10.05%, THTX belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
  • THTX has a better Gross Margin (77.72%) than 83.96% of its industry peers.
  • THTX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.05%
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so THTX is creating value.
  • The number of shares outstanding for THTX remains at a similar level compared to 1 year ago.
  • THTX has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for THTX is higher compared to a year ago.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -8.27, we must say that THTX is in the distress zone and has some risk of bankruptcy.
  • THTX's Altman-Z score of -8.27 is on the low side compared to the rest of the industry. THTX is outperformed by 70.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.27
ROIC/WACC4.64
WACC11.93%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.84 indicates that THTX may have some problems paying its short term obligations.
  • The Current ratio of THTX (0.84) is worse than 89.37% of its industry peers.
  • A Quick Ratio of 0.65 indicates that THTX may have some problems paying its short term obligations.
  • THTX's Quick ratio of 0.65 is on the low side compared to the rest of the industry. THTX is outperformed by 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.65
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for THTX have decreased by 0.00% in the last year.
  • THTX shows a small growth in Revenue. In the last year, the Revenue has grown by 2.19%.
  • THTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.31% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%

3.2 Future

  • Based on estimates for the next years, THTX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.71% on average per year.
  • THTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.44% yearly.
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for THTX. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 24.08 indicates a rather expensive valuation of THTX.
  • Based on the Price/Forward Earnings ratio, THTX is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of THTX to the average of the S&P500 Index (28.02), we can say THTX is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 24.08
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of THTX indicates a rather cheap valuation: THTX is cheaper than 94.22% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.18
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • THTX's earnings are expected to grow with 46.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.79%
EPS Next 3Y46.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for THTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

THERATECHNOLOGIES INC

NASDAQ:THTX (9/25/2025, 8:03:14 PM)

After market: 3.4 +0.01 (+0.29%)

3.39

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-09
Earnings (Next)10-08
Inst Owners22.29%
Inst Owner Change-99.26%
Ins Owners0.9%
Ins Owner ChangeN/A
Market Cap155.87M
Revenue(TTM)84.38M
Net Income(TTM)-9.16M
Analysts84
Price Target4.09 (20.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-291.26%
Min EPS beat(2)-482.52%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-224.76%
Min EPS beat(4)-482.52%
Max EPS beat(4)94.17%
EPS beat(8)5
Avg EPS beat(8)-62.95%
EPS beat(12)6
Avg EPS beat(12)-46.18%
EPS beat(16)6
Avg EPS beat(16)-49.02%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)-1.91%
Revenue beat(4)1
Avg Revenue beat(4)-3.24%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-5.3%
Revenue beat(12)1
Avg Revenue beat(12)-6.15%
Revenue beat(16)1
Avg Revenue beat(16)-7.55%
PT rev (1m)0.63%
PT rev (3m)-1.02%
EPS NQ rev (1m)-166.67%
EPS NQ rev (3m)-125%
EPS NY rev (1m)0%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)-7.92%
Revenue NQ rev (3m)-10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.08
P/S 1.85
P/FCF N/A
P/OCF 22.15
P/B N/A
P/tB N/A
EV/EBITDA 18.18
EPS(TTM)-0.19
EYN/A
EPS(NY)0.14
Fwd EY4.15%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0.15
OCFY4.51%
SpS1.84
BVpS-0.61
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROCE 70.09%
ROIC 55.37%
ROICexc 307.38%
ROICexgc N/A
OM 10.05%
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score4
Asset Turnover1.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.84
Cap/Depr 519.63%
Cap/Sales 11.98%
Interest Coverage 1.21
Cash Conversion 67.47%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.65
Altman-Z -8.27
F-Score4
WACC11.93%
ROIC/WACC4.64
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%
EBIT growth 1Y125.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y28.68%
FCF growth 1Y82.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.06%
OCF growth 3YN/A
OCF growth 5YN/A

THERATECHNOLOGIES INC / THTX FAQ

What is the fundamental rating for THTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to THTX.


Can you provide the valuation status for THERATECHNOLOGIES INC?

ChartMill assigns a valuation rating of 4 / 10 to THERATECHNOLOGIES INC (THTX). This can be considered as Fairly Valued.


What is the profitability of THTX stock?

THERATECHNOLOGIES INC (THTX) has a profitability rating of 4 / 10.